CSI Medical

Cardiovascular Systems, commonly known as CSI, is a vascular intervention medical device company focused on atherectomy systems for the treatment of peripheral and coronary artery disease. Its core commercial products include the Diamondback 360 and Stealth 360 orbital atherectomy systems, which are used to modify calcified and fibrotic arterial plaque prior to angioplasty or stenting. The company built its business around catheter-based vessel-preparation devices for complex arterial disease and also had an early-stage pipeline of complementary vascular intervention devices. In 2023, CSI was acquired by Abbott and now operates as part of Abbott's cardiovascular device portfolio. The requested name "CSI Medical" most likely refers to this company in the healthcare/medtech context, although the exact legal company name was Cardiovascular Systems rather than CSI Medical.